Industry 5.0 Market: Proliferation of 3D printing technology in the manufacturing of medical equipment and customized drugs
The global Industry 5.0 market size was valued at USD 65.8 billion in 2024 and is estimated to reach USD 255.7 billion by 2029, registering a CAGR of 31.2% during the forecast period.
The Industry 5.0 market share is rapidly expanding, driven by technological advancements in AI, IoT, robotics, and 3D printing that enable manufacturers to automate processes, personalize products, and increase efficiency. Customer demands for more customized, sustainable, and rapidly updated products necessitate flexible and adaptable manufacturing models. Finally, the growing need for resilience in the face of disruptions and sustainability concerns has led Industry 5.0 to prioritize resource optimization, adaptability, and worker well-being, creating an impactful market landscape.
The widespread adoption of 3D printing technology in manufacturing medical equipment and customized drugs within Industry 5.0 has fostered a promising environment full of opportunities. This upsurge is reshaping the landscape by offering increased flexibility, accuracy, and personalization in the production processes of medical devices and pharmaceuticals.
Download PDF Brochure @
领英推荐
Stratasys, a key player in 3D printing solutions, offers BioMimics, enabling the development of highly realistic, patient-specific anatomical models. These models have various applications, including surgical planning, medical training, and the creation of tailored medical devices.
Aprecia Pharmaceuticals introduces 3D-printed pharmaceuticals like SPRITAM, featuring precise dosage control and rapid disintegration to enhance patient adherence. Additionally, Organovo's expertise in bioprinting focuses on creating 3D-printed human tissues, revolutionizing medical research and drug testing with personalized and functional tissue constructs. This technological advancement showcases how 3D printing in Industry 5.0 enhances the efficiency of medical equipment and pioneers personalized medicine, marking a transformative shift in healthcare innovation.
The industry 5.0 companies is dominated by a few globally established players such as: